Contribute Try STAT+ Today

Top of the morning to you, and a fine one, it is. Despite another round of overcast skies enveloping the Pharmalot campus, we are maintaining a stiff upper lip and a sunny outlook. After all, as the Morning Mayor taught us: Every new day should be unwrapped like a precious gift. While you tug on the ribbon, we will fire up the coffee kettle for another cup of stimulation. Meanwhile, here are a few items of interest to stimulate your own neurons. Hope your day is successful and, as always, please do keep in touch.

Another, less likely victim of the outbreak: India’s pharmaceutical industry, The South China Morning Post explains. India imports nearly 70% of its raw materials and active ingredients from China, about $4.5 billion each year. Since 2015, pharmaceutical ingredients have been among India’s top 10 imports from China and a sizable chunk of these were used in the $19.1 billion worth of pharmaceutical products that the latter exported last financial year, according to official figures.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.